- Home
- CDLR vs ADPT Comparison
CDLR vs ADPT Comparison
Compare CDLR & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDLR
- ADPT
- Stock Information
- Founded
- CDLR 2008
- ADPT 2009
- Country
- CDLR Denmark
- ADPT United States
- Employees
- CDLR N/A
- ADPT N/A
- Industry
- CDLR
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CDLR
- ADPT Health Care
- Exchange
- CDLR Nasdaq
- ADPT Nasdaq
- Market Cap
- CDLR 1.9B
- ADPT 2.0B
- IPO Year
- CDLR N/A
- ADPT 2019
- Fundamental
- Price
- CDLR $18.90
- ADPT $17.68
- Analyst Decision
- CDLR
- ADPT Strong Buy
- Analyst Count
- CDLR 0
- ADPT 10
- Target Price
- CDLR N/A
- ADPT $14.10
- AVG Volume (30 Days)
- CDLR 90.9K
- ADPT 2.0M
- Earning Date
- CDLR 11-25-2025
- ADPT 11-05-2025
- Dividend Yield
- CDLR N/A
- ADPT N/A
- EPS Growth
- CDLR N/A
- ADPT N/A
- EPS
- CDLR 0.78
- ADPT N/A
- Revenue
- CDLR $546,159,718.00
- ADPT $205,216,000.00
- Revenue This Year
- CDLR $143.84
- ADPT $32.63
- Revenue Next Year
- CDLR $66.36
- ADPT $16.31
- P/E Ratio
- CDLR $6.20
- ADPT N/A
- Revenue Growth
- CDLR 277.89
- ADPT 21.60
- 52 Week Low
- CDLR $17.37
- ADPT $4.27
- 52 Week High
- CDLR $27.86
- ADPT $17.62
- Technical
- Relative Strength Index (RSI)
- CDLR 32.52
- ADPT 70.98
- Support Level
- CDLR $19.50
- ADPT $16.29
- Resistance Level
- CDLR $20.35
- ADPT $17.62
- Average True Range (ATR)
- CDLR 0.53
- ADPT 0.76
- MACD
- CDLR -0.25
- ADPT 0.22
- Stochastic Oscillator
- CDLR 5.19
- ADPT 95.29
About CDLR Cadeler AS
Cadeler AS is an offshore wind farm vessel contractor. It is engaged in offshore wind farm construction, maintenance, and decommissioning and provides marine and engineering operations to the wind industry, focusing on safety and the environment. The company operates six offshore jack-up wind farm installation vessels. In addition to wind farm installation, these vessels can perform maintenance, construction, decommissioning, and other tasks within the offshore industry.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).